top of page

Search Results

39 items found for ""

  • Wearables Using Photoplethysmography Sensors for Non-Invasive Blood Glucose Detection Validated

    A local study shows that sensors commonly found in wearables can aid in the non-invasive detection of elevated blood glucose levels (Image source: Stock image) Singapore, 10 October 2024  – Imagine detecting the risk of diabetes with a wearable device, allowing for early intervention through positive lifestyle changes to delay or even prevent the development of this chronic disease.   Type 2 diabetes mellitus (T2DM) is a global non-communicable disease, with cases surging from 108 million in 1980 to 422 million in 2014[1]. Recognising the importance of early detection and intervention, Actxa Pte Ltd (Actxa) partnered with KK Women’s and Children’s Hospital (KKH) on a research study.   This study, “ Utility of photoplethysmography in detecting elevated blood glucose among non-diabetics” , recently published in the Singapore Medical Journal, shows that using photoplethysmography (PPG) signals (the green or red light on most wearables that measure heart rate), a non-invasive method of assessing T2DM risk, is a viable option to provide a more cost-effective and more accessible modality for screening in the community. The full study can be accessed here .      From October 2021 to February 2023, healthy volunteers were recruited at KKH. 483 volunteers’ capillary glucose levels were measured alongside PPG signals using Actxa’s Spark + Series 2 activity tracker and an in-ear wearable. The volunteers were evaluated over eight minutes to obtain accurate PPG readings.     Participants with capillary glucose levels of 11.1 mmol/dL or less consumed a standard glucose tolerance drink (TRUTOL. 75 g) and returned one hour later for a follow-up test. In contrast, those with readings exceeding 11.1 mmol/dL were exempted from the glucose tolerance drink. This methodology ensured the thorough evaluation of blood glucose levels, thereby enhancing the reliability of the study’s findings.    This research leverages the innovative use of PPG sensors to monitor and evaluate increased blood glucose levels non-invasively. The study has revealed that non-invasive diabetes risk assessment using PPG is a practical and cost-effective method for population-wide screening. This non-invasive nature of the PPG approach makes it accessible, encouraging early detection and allowing individuals to adopt timely positive lifestyle changes and seek medical interventions before more severe complications develop.    This study has also demonstrated the capabilities of Actxa’s Blood Glucose Evaluation & Monitoring (BGEM) technology, the world’s first non-invasive diabetes risk assessment powered by an AI-driven algorithm. BGEM is a cloud-based technology that can be seamlessly integrated into wearable devices with PPG sensors to assess the risk of impaired glucose regulation.     As countries grapple with rising healthcare costs related to diabetes care, this technology can potentially reduce long-term healthcare burden by focusing on prevention. Early detection enables individuals to make lifestyle changes that can prevent or delay the onset of T2DM, ultimately leading to healthier populations and more sustainable healthcare systems.    Marcus Soo, Chief Executive Officer of Actxa, said , “In our pursuit of innovative solutions to address global health challenges, Actxa is proud that our technology has been validated through a local study. We are on track to reveal a transformative breakthrough in how we evaluate prediabetes and T2DM risk using PPG sensors.     Actxa’s BGEM technology, which integrates into wearables with PPG sensors, offers a cost-effective and scalable method for non-invasive blood glucose risk assessment, positioning us at the forefront of preventive health technology.     The opportunities here are paradigm-shifting—a wearable device on your wrist, finger, or ear could detect early diabetes risks, enabling individuals to make proactive lifestyle changes. This collaboration reflects our commitment to pushing preventive healthcare innovation, making early detection and prevention accessible for all. Together with our partners, we are charting the course towards a healthier future for individuals and our communities.”    Future developments will involve incorporating various non-invasive detection sensors to enhance sensitivity and specificity, enabling better management of T2DM through non-invasive methods alongside capillary glucose measurements.   Reference:   1. WHO Factsheet on Diabetes: https://www.who.int/news-room/fact-sheets/detail/diabetes     For further information, please contact:   ​Tan Lay Eng   Communications Manager  layeng.tan@actxa.com   +65 9877 0406  Hasyimah Begum AJ  Communications Executive  hasyimah.aj@actxa.com   +65 8780 3620   About Actxa   Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​  We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​   To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​     ​Learn more about Actxa at www.actxa.com .

  • Actxa’s BGEM: The World’s First Non-Invasive Blood Glucose Monitoring Solution Powered by AI

    Singapore, 17 October 2024  —Actxa Pte Ltd, a Singapore-based deep tech company, introduces its Blood Glucose Evaluation & Monitoring (BGEM) technology . Powered by a cloud-based AI-driven algorithm, BGEM offers a non-invasive solution for blood glucose monitoring, marking a new approach to early diabetes detection and management. Diabetes: A Growing Concern In Singapore, it is projected that by 2050, at least 1 million people will be living with diabetes, with 1 out of 4 remaining undiagnosed¹. Globally, the number of diabetic individuals is expected to reach about 643 million by 2030, with 1 in 2 adults undiagnosed². Undiagnosed diabetes poses severe risks, as early-stage symptoms are often silent, leading to delayed diagnosis and potentially irreversible complications. Regular glucose monitoring is essential for detecting the risk of diabetes early, which enables timely and life-saving interventions. A Non-Invasive Approach to Blood Glucose Monitoring BGEM leverages advanced photoplethysmography (PPG) sensors to offer a non-invasive blood glucose monitoring solution. By integrating this technology into wearables, BGEM allows users to monitor their diabetic risk assessment regularly. This could support and promote early intervention, leading to better health outcomes while reducing long-term pain and cost for individuals.  A joint study by Actxa and KK Women’s and Children’s Hospital (“KKH”), titled   “Utility of photoplethysmography in detecting elevated blood glucose among non-diabetics” and published in the Singapore Medical Journal, validates the effectiveness of PPG sensors in its non-invasive blood glucose detection. The study highlights BGEM’s capabilities in integrating wearable devices with PPG sensors to assess the risk of impaired glucose regulation. The full study can be accessed here .   BGEM leverages wearables with PPG sensors to collect essential data, in which an AI model computes the relevant digital biomarkers correlated with prediabetes or Type 2 Diabetes Mellitus (T2DM) to assess diabetic risk and generate predicted blood glucose results to support early intervention. [Image Source: Actxa] Clinical Validation and Global Partnerships BGEM underwent its first clinical trials in 2022, with its first scientific paper published in 2023. The technology has garnered attention for its potential in non-invasive blood glucose monitoring. Actxa continues to collaborate with international partners to explore the broader potential of BGEM, bringing it to markets globally while remaining committed to advancing local innovations in Singapore. Alleviating Financial Strain Through Diabetes Prevention With diabetes on the rise globally, the focus is shifting from reactive treatment to proactive prevention. BGEM’s early detection capabilities enable individuals to make lifestyle changes that can prevent or delay the onset of Type 2 diabetes mellitus (T2DM). By reducing the burden of long-term diabetes management, BGEM contributes to healthier populations and more sustainable healthcare systems. In Singapore, the healthcare system faces significant strain due to the rising number of diabetes cases, with around $940 million spent on diabetes-related care in 2017³. By enabling earlier detection and intervention, BGEM has the potential to ease this burden, contributing to more sustainable healthcare outcomes. Innovating for a Healthier Future Marcus Soo, Chief Executive Officer of Actxa, said , “As a company with a vision to help people live healthier and longer lives through technology, we are dedicated to translating technological innovations into evident solutions that enhance lives. BGEM simplifies the monitoring process, allowing users to gain insights into their health regularly and non-invasively. By continuing to collaborate with partners and refine our technology, we hope to empower more individuals to manage their health proactively. We believe this can lead to better outcomes and support the sustainability of healthcare systems.” Actxa is committed to improving the lives of those affected by diabetes through cutting-edge technology and meaningful collaborations. References: https://www.healthhub.sg/live-healthy/1273/d-day-for-diabetes https://idf.org/aboutdiabetes/what-is-diabetes/factsfigures.html#:~:text=The%20total%20number%20of%20people,living%20with%20dia   betes%20are%20undiagnosed   https://www.moh.gov.sg/news-highlights/details/percentage-of-spending-on-mental-health-diabetes-and-ageing-versus-total-healthcare-spending-in-2018-against-amount-budgeted-for-2019/   For further information, please contact:   ​Tan Lay Eng   Communications Manager  layeng.tan@actxa.com   +65 9877 0406  Hasyimah Begum AJ  Communications Executive  hasyimah.aj@actxa.com   +65 8780 3620   About Actxa   Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​  We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​   To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​     ​Learn more about Actxa at www.actxa.com .

  • Actxa and Diabetes and Hypertension Clinic Collaborate for Research on Diabetes Prevention with Artificial Intelligence in India

    10 June 2024   – Actxa Pte Ltd (“Actxa”), a Singaporean AI-driven deep tech company, has entered a Memorandum of Understanding (“MOU”) with the Diabetes and Hypertension Clinic (“DHC”) in India, a diabetes evaluation and management centre. The MOU, signed on 6 June 2024, marks a strategic step for Actxa to further research on diabetes prevention with artificial intelligence (“AI”) in India.   Since 2017, Actxa has been collaborating with research and medical institutions in Singapore in the research and development of non-invasive technology for detecting blood glucose elevation and diabetic risk assessment. The company completed its first clinical trial in 2022 and published its first scientific paper in 2023.  Actxa’s BGEM is the world’s first non-invasive blood glucose monitoring solution powered by an AI-driven algorithm that enables wearables and hearables with Photoplethysmography (PPG) sensors to assess the risk of impaired glucose regulation.​   In India, an estimated 77 million people above the age of 18 suffer from T2DM, with nearly 25 million classified as prediabetic [1]. Individuals with diabetes are at a higher risk for serious health issues, including heart attack, stroke and kidney failure. Over time, T2DM can damage blood vessels in the heart, eyes, kidneys and nerves [2].   This MOU seeks to broaden the study of non-invasive blood glucose monitoring using artificial intelligence in the Indian population. If successful, the non-invasive solution will be an affordable and user-friendly approach to promoting regular monitoring of blood glucose elevation and diabetic risk in India. Marcus Soo , Chief Executive Officer of Actxa , said, “We are happy to work with like-minded professionals like Dr. Abhinav Gupta of DHC. This collaboration showcases commitment from both Actxa and DHC, and our dedication to improving the lives of individuals affected by diabetes through innovation and excellence using advanced science and AI technology. Together with DHC, we aim to empower individuals in India with valuable insights into their diabetic health.”   Dr. Abhinav Gupta, MBBS, MD, FRCP, Professor of Medicine at ASCOMS,  shared, “Our collaboration with Actxa represents a pivotal milestone in our journey in advancing diabetes prevention and care.  Through research on AI-based algorithms for detecting hyperglycemia in diabetes patients, we are poised to make significant strides in early detection and treatment. This partnership underscores our dedication to harnessing cutting-edge technology for better health outcomes, aligning with the innovative BGEM technology.”   This collaboration between Actxa and DHC paves the way for groundbreaking advancements in diabetes prevention and care, contributing to a healthier future for individuals in Singapore, India and worldwide.    References: 1. World Health Organization, Diabetes in India: https://www.who.int/india/health-topics/mobile-technology-for-preventing-ncds 2. World Health Organization, Diabetes: https://www.who.int/news-room/fact-sheets/detail/diabetes     For further information, please contact: ​Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620    About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​   ​Learn more about Actxa at www.actxa.com .   About Diabetes and Hypertension Clinic   Diabetes and Hypertension Clinic is a daycare setting run by Dr. Abhinav Gupta, who is a pioneer in the management of Diabetes and Hypertension. He has more than 15 years of experience in DHC, which is located in Channi Himmat Jammu, J&K, India.   Dr. Gupta has been awarded a fellowship of the Royal College of Physicians of London, Edinburgh and Glasgow.

  • Singapore’s Actxa and Indonesia’s Universitas Kristen Krida Wacana Collaborate to Lead AI-Driven Chronic Disease Prevention

    25 July 2024  – Actxa Pte Ltd (“Actxa”), a Singaporean AI-driven deep tech company, has entered a Memorandum of Understanding (“MOU”) and a Research and Collaboration Agreement (“RCA”) with Universitas Kristen Krida Wacana (“UKRIDA”), a prominent private institution of higher education that has been committed to education, research, and community service for 56 years in Indonesia, with its Faculty of Medicine and Health Sciences being the oldest at the university.     The MOU and RCA, signed on 24 July 2024, mark a significant milestone for Actxa as it embarks on a collaborative partnership focusing on joint research, product development, higher education, human resources development, and community services in artificial intelligence (“AI”) based chronic disease management. UKRIDA, whose mission is to be at the forefront of healthcare science development, has embraced Artificial intelligence as an avant-garde, innovative technology as a major focus for UKRIDA’s Research and Development efforts. This joint project, therefore, will bring great benefit to both Actxa and UKRIDA, whose interests are perfectly matched.     Since 2017, Actxa has been at the forefront of collaborations with research and medical institutions in Singapore and globally, focusing on developing life-changing preventive health technologies and solutions using AI.  One of Actxa’s most significant achievements is BGEM , the world’s first non-invasive blood glucose monitoring solution. Powered by a cloud-based AI-driven algorithm, BGEM integrates seamlessly with smart wearables and hearables using Photoplethysmography (PPG) sensors to assess the risk of impaired glucose regulation.    UKRIDA’s interest in developing healthcare based on innovative technology has found BGEM to have great potential in glucose metabolism evaluation and control, especially since diabetes mellitus is one of the major metabolic diseases that needs to be prevented and controlled. The joint project with Actxa to further develop BGEM capabilities and adapt them to the Indonesian population will enable UKRIDA to be a pioneer in chronic disease prevention and control technology in Indonesia.  ​   This strategic partnership enables Actxa and UKRIDA, with its motto “Lead to Impact”, to jointly pioneer research and development initiatives leveraging cutting-edge technologies such as AI, Machine Learning (“ML”), and Big Data Analytics. Their collaborative efforts aim to detect, delay, or prevent the onset of chronic diseases. This alliance fosters innovation through the co-creation of healthcare solutions and advanced technologies, coupled with rapid prototyping, to accelerate the market introduction of these products and technologies.    Marcus Soo , Chief Executive Officer of Actxa , said, “We are honoured to partner with UKRIDA, marking a significant milestone for Actxa as we embark on our very first collaboration with an Indonesian university conducting research within a hospital setting. This partnership reflects our shared commitment to innovation and empowering individuals with tools to make informed and positive lifestyle decisions.  We extend our gratitude to our joint venture partner, LIF, for their pivotal role in this close partnership, facilitating our efforts in Indonesia. Together, we aim to drive global innovation in preventive healthcare, leveraging our combined expertise to make meaningful strides in chronic disease prevention and management.”  Prof. Dr.-Ing. Ir. Herman Parung, M.Eng, Rector of UKRDIA, shared, “Both Actxa and UKRIDA share a profound commitment to innovation and the advancement of preventive healthcare solutions. This partnership is poised to accelerate the development of advanced healthcare solutions, ultimately contributing to better health and well-being for individuals and communities.” He also added, “We are confident that this partnership will yield significant advancements in healthcare and foster a strong bond between our institutions.”  This partnership between Actxa and UKRIDA heralds groundbreaking innovations in chronic disease prevention and management, working towards building a healthier future for individuals in Singapore, Indonesia, and worldwide. This joint project will also be an example of UKRIDA’s commitment to developing health science based on innovative technology and its effort to build strategic partners from national, regional, and international circles to bring greater progress and benefit to society.  For further information, please contact:     ​Tan Lay Eng  Communications Manager  layeng.tan@actxa.com   +65 9877 0406  Hasyimah Begum AJ  Communications Executive  hasyimah.aj@actxa.com   +65 8780 3620   About Actxa   Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions.   We create evidence-based, personalized health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​  To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​  ​Learn more about Actxa at www.actxa.com .

  • Actxa & KK Women’s and Children’s Hospital Research Non-invasive Blood Glucose Monitor on Wearables

    For immediate release Singapore, 27 September 2021 – Actxa and KK Women’s and Children’s Hospital (KKH) are carrying out a clinical study to validate a non-invasive blood glucose predictive model on wearable devices with photoplethysmography (PPG) sensors developed by Actxa. The roles of wrist-worn and in-ear wearables with PPG sensors are constantly evolving. From being a lifestyle device that monitors sports and activities, to a device that monitors a person’s lifestyle well-being and health, foraying into preventive healthcare, particularly for the prevention of chronic diseases. Diabetes has been one of the “silent” chronic diseases, and research has shown that diabetic patients have a two to three-fold higher risk of developing cardiovascular disease. In Singapore and globally, diabetes and cardiovascular diseases are serious health concerns resulting in poor quality of life. Leveraging on its expertise and knowledge of wrist-worn and in-ear wearables, Actxa has developed a predictive model based on Artificial Intelligence and Machine Learning (AIML) for PPG sensors to monitor blood glucose level non-invasively. The collaboration with KKH will enable Actxa to externally validate the predictive model developed against an independent population, further improving the model’s diagnostic ability. Joel Chin, CEO of Actxa, said, “We are excited about this collaboration as the predictive model will be able to facilitate early detection and intervention of diabetes that will make a significant positive impact in the preventive health arena. It will also provide valuable insights into wearables’ potential in providing continuous and accurate real-time data that can aid patients, whose blood sugar is in the diabetes and pre-diabetes range, to self-manage their disease better and earlier.” Associate Professor Ang Seng Bin, Head and Senior Consultant, Family Medicine Service, KKH, who is also the principal investigator of this research at KKH, said, “As Singapore’s largest academic medical centre specialising in women’s and children’s health, KKH is committed to improving patient health outcomes. Through this new collaboration, we hope that we can harness the power of technology to make a difference in patients’ lives, especially those with diabetes.” This clinical study will be carried out jointly by the following Principal Investigators – Associate Professor Ang Seng Bin (KKH), Emeritus Professor Satvinder Singh Dhaliwal (Actxa) and Mr Shi Bohan (Actxa). Results and findings from this clinical study are to be published in the second half of 2022 in peer-reviewed scientific journals. Actxa will carry out more clinical trials in the near future to provide further clinical evidence for new products. About Actxa Headquartered in Singapore, Actxa Pte.Ltd (“Actxa”) was founded in 2015 with the mission to have deep empathy and harness the power of science and data to empower people to lead healthier lives. At Actxa, we inspire individuals from all walks of life to make proactive moves to live better and healthier. Leveraging data analytics, artificial intelligence, and machine learning, we create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and non-invasive blood glucose monitoring. With the help of these insights, Actxa develops applications such as Healthy Living Score (HLS), Actxa Wellness Programme (AWP) and products to empower individuals to manage and improve their own health. To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension. Good health and happiness go hand-in-hand. Actxa is committed to taking the lead to create Better Moves, Better Lives to better ourselves, the people around us and our community. For further information, please contact: Tan Lay Eng Corporate Communications Manager layeng.tan@actxa.com +65 98770406

  • 【到底购了没?】体质分析就靠它! | “X光”卡通快收藏

    (Media source: MediaCorp 8world) Actxa 健康分析 Actxa迎来专业级别的智能体重秤和身体成分分析仪“Sense 2 Smart Scale”。这个新品的研发乃基于其第一代的成功,“Sense 2”的出现,则具有更高的准确性和更多的定制化,可提供分段成分分析报告,帮助个人改善健康状况。 此新品采用了八个触觉电极和双频生物电阻抗分析 (BIA) 技术,可评估多达11项的基本身体测量值,为用户提供包含 20 多项身体成分指标的整体分析报告。 它还会显示最近十次的测量值趋势,让用户能够监控及跟踪自己的体重、肌肉质量和体脂百分比 (PBF) 的变化。 “Sense 2”可支持多个用户的使用,让一家人一起实现健康目标。售价$150。 哪里买:https://tinyurl.com/yck6wfct

  • Actxa and Umeox Enter Strategic Collaboration with Integration of BGEM

    19 October 2023 – Actxa, a Singapore-based AI-driven deep tech company, and Umeox, a leader in wearables manufacturing and solutions, have entered a strategic collaboration to integrate Actxa’s cutting-edge non-invasive Blood Glucose Evaluation & Monitoring solution, BGEM, into Umeox’s upcoming product lineup, including health rings and smartwatches. BGEM by Actxa is the world's first non-invasive blood glucose monitoring solution that leverages the latest technological advancement in signal processing, wearable technologies, and artificial intelligence (“AI”) to assess the risk of impaired glucose regulation. The heart of BGEM lies in its ability to use inter-beat-interval data from a consumer-grade wearables photoplethysmography (“PPG”) sensor. Using its advanced AI model, BGEM computes the relevant digital biomarkers correlated with the symptoms of prediabetes or Type 2 diabetes mellitus (“T2DM”) that eventually predicts the risk of developing diabetes. A powerful health awareness tool, BGEM empowers individuals to monitor and assess their glucose dysregulation in a non-invasive, easy and frequent manner. With continuous monitoring and evaluation of diabetic risks, individuals can take proactive measures in making informed health decisions and positive lifestyle changes to reduce the risk of T2DM development. Marcus Soo, Chief Executive Officer of Actxa, said, “As a company with a vision to help people live healthier and longer with technology, we aspire to translate technological innovations into evident solutions that enhance lives. Collaborating with pioneering industry players like Umeox aligns with our vision. The fusion of their products with our BGEM solution holds the potential to empower more people to take proactive actions to prevent, delay the onset or even reverse the condition of diabetes. This strategic collaboration not only expedites the development, market accessibility and future commercialisation of BGEM but also tangibly contributes to building healthier individuals and communities. We look forward to a successful partnership with Umeox.” Jack Shao, Founder and Chief Executive Officer of Umeox, said, “Over the course of 17 years, we have remained dedicated to empowering people to live healthier. Our products have consistently demonstrated their ability to enhance people’s overall well-being. We believe our latest smart ring model, X ring, has immense potential to positively transform preventive healthcare and empower individuals to take control of their well-being through continuous, unobtrusive health monitoring. Working in tandem with Actxa to integrate BGEM into our upcoming product releases enables us to address evolving consumer needs effectively. This strategic collaboration reflects the shared commitment of both companies to unlock new opportunities in the global preventive health market, and we hope this strategic collaboration will be a great start for the two parties’ long-term partnership.” BGEM has won Actxa an award under the AI – Healthcare Technology category in the annual SBR Technology Excellence Awards 2022, hosted by Singapore Business Review. For further information, please contact: About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​ ​Learn more about Actxa at www.actxa.com. About Umeox Umeox is a high-tech and innovative enterprise of software, hardware, service integrated Solution. It develops and produces intelligent terminals which are based on IoT and AI technology, as well as providing operators and vendors around the world with one-stop solution services, including hardware manufacturing, software development, location management, AI interaction, health care, and intelligent data management cloud platform. Based on strong R&D ability and professional service, Umeox always adheres to high-quality strategy, keeps up with hot market demand and trend, constantly explores cutting-edge technology of scientific and technological innovation, closely combines humanistic care, and continuously provides customers with high-quality and cost-effective customised products and full turnkey solutions. ​Learn more about Umeox at www.umeox.com.

  • Actxa and Instytut Medycyny Innowacyjnej sp.z o.o Introduce BGEM in Poland

    4 April 2024 – Actxa Pte Ltd (“Actxa”), an AI-driven deep tech company headquartered in Singapore, has signed a Memorandum of Agreement (“MOU”) with Instytut Medycyny Innowacyjnej sp.z o.o. (“IMI”), a research and medical technologies institute based in Poland on 7 March 2024. This MOU marks the beginning of a strategic partnership for collaboration and market distribution of Actxa’s BGEM, a non-invasive Blood Glucose Evaluation and Monitoring Technology and other Actxa technologies in Poland. At the heart of this partnership is Actxa’s groundbreaking BGEM technology - the world's first non-invasive blood glucose monitoring technology. Harnessing the power of artificial intelligence ("AI"), wearable technologies and signal processing, BGEM tracks and identifies the risk of impaired glucose regulation. By analysing inter-beat-interval data from consumer-grade wearables equipped with photoplethysmography ("PPG") sensors, BGEM calculates the digital biomarkers associated with prediabetes or Type 2 diabetes mellitus ("T2DM") symptoms, empowering users to monitor, track, and identify fluctuations in their blood glucose levels. This proactive approach allows users to implement timely lifestyle adjustments, effectively mitigating the risk or delaying the onset of diabetes. Under this partnership, IMI will be an authorised licensee with the rights to use BGEM and incorporate the technology in its brand of wearable products for distribution in Poland. Additionally, IMI will play a pivotal role in facilitating the exploration of opportunities within countries, governments and industries to sell and market wearables with BGEM and other Actxa technologies. Marcus Soo, Chief Executive Officer of Actxa, said, “Our collaboration with IMI signifies an important milestone in our journey toward global expansion. This collaboration is a testament to our commitment to innovation and excellence in the tech industry. Together with IMI, we embark on a transformative endeavour, combining our strengths to propel our business to new heights internationally. This alliance not only strengthens our position in the global market but also allows our technologies, such as BGEM, to benefit a broader community. As we join forces with IMI, we are poised for unparalleled growth, setting the stage for a future defined by international success and groundbreaking achievements.” Founder of IMI, Professor Mieczysław Pasowicz shared, “At IMI, we are driven by a shared vision for a future where healthcare is transformed through innovation. Our collaboration with Actxa speaks to our unwavering dedication as we bring their groundbreaking technologies to Poland. Our strategic partnership aims to revolutionise healthcare, fostering a future where cutting-edge solutions positively impact lives. This partnership represents a significant stride towards a healthier and more technologically advanced world.” This alliance between Actxa and IMI sets the stage for Actxa’s innovative technologies to expand globally. As both companies continue to leverage their strengths and expertise, they are poised to drive positive change and contribute to the advancement of a healthier world. For further information, please contact: About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​ ​Learn more about Actxa at www.actxa.com. About Instytut Medycyny Innowacyjnej sp.z o.o For nearly 30 years Prof. Mieczysław Pasowicz has been creating and implementing initiatives related to the adaptation of hospitals to European Union standards through the creation and implementation of innovative investment projects. He specializes in investment and hospital development, healthcare management and training and digital transformation. It promotes the development of personalized medicine, coordinated healthcare and digital medicine. This is possible thanks to the involvement in modern technologies, advanced treatment methods and continuous training of medical personnel. Prof. Mieczysław Pasowicz is the founder and president/CEO of the Institute. The Institute of Innovative Medicine is a spin-off company established to commercialize research and implement new medical technologies. The company is the initiator of the creation of the BioMedTech Technology Park, the aim of which is to transfer technology from Asia to Europe and is currently looking for Partners and Investors interested in co-creating the Longevity Technology Park using the latest developments in medical robotics,  biotechnology, IT, artificial intelligence and other medical technologies. It already has a modern facility with an area of 18 thousand m2 and an investment area for the creation of the Park (www.medtechpoland.eu). Leading programs promoting organizational, product and technological innovations, the Institute of Innovative Medicine together with its partners achieves better results and market position in many areas. The Institute provides consulting and training services, provides specialized IT systems and medical equipment and offers management of healthcare facilities. It has several medical teams and cooperates with more than 100 specialists both at home and abroad. The Institute and BioMedTech Park will support young companies, innovative products and proven technologies, introducing them to domestic and international markets on behalf of customers and through sales programs. Prof. Dr hab. med. Mieczysław Pasowicz is a long-time director of the John Paul II Hospital in Krakow and vice-president of the European Association of Hospital Managers (EAHM). He is the founder and also serves as the president of the Polish Association of Hospital Directors. Prof. Pasowicz is a long-term academic lecturer with significant medical, scientific and organizational achievements.

  • Actxa Participates in AI Asia Expo Thailand 2023

    Singapore, 14 February 2023 –Actxa Pte Ltd (“Actxa”) is proud to present our award-winning Blood Glucose Evaluation & Monitoring (BGEM) and AI-driven preventive healthcare solutions at the AI Asia Expo in Thailand. Date: 21 and 22 February 2023 Location: Centara Grand at Central Plaza, Ladprao Bangkok, Thailand Booth number: 26 (Singapore Pavilion) Actxa will also be sharing how AI in preventive healthcare complement conventional healthcare. Do catch us at the following date and time: Date: 22 February 2023 Time: 12 pm to 12.30 pm Speaker: Alex Loh | Vice President of Digital Wellness Solution CEO of Actxa Wellness Pte Ltd (a subsidiary of Actxa) Topic: Application of AI Technologies for Preventive Healthcare For further information, please contact: Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620

  • Spurring a nation to get active: Step up & out with the Actxa Swift and Swift+

    For Immediate Release SPURRING A NATION TO GET ACTIVE: STEP UP & OUT WITH THE ACTXA SWIFT AND SWIFT+ SINGAPORE (28 October 2016) – Actxa is proud to be appointed as one of the official technology partners of the National Steps Challenge (NSC) Season 2 by the Health Promotion Board (HPB). Fueled by the nation’s positive response to the physical activity initiative last year, the fitness wearables company has launched three new step tracker models alongside an easy trade-up program, to help Singapore step up and out for NSC Season 2. Launched by HPB on 1 October 2016, Season 2 brings more fun and prizes in motivating the nation to step up and move about every day, anytime and anywhere. Making a welcome return from last year is the immensely popular steps-for-rewards system, where all NSC participants will be rewarded for leading active lifestyles – the more steps taken each day, the more points earned to redeem sure-win rewards as well as lucky draw chances. The smart gadget tagged to this fun physical activity programme is the steps tracker, a pedometer-based fitness buddy designed to motivate even more Singaporeans to lead active lifestyles. A firm advocate of spurring a nation of physically active people, Actxa came on board last year to supply the wearable technology, and 2015 saw HPB handing out over 156,000 pieces of the specially produced Actxa Stride – which can still be used for the second season of NSC. In addition, Actxa has produced three enhanced step tracker models: The Stride+, as well as the Swift and Swift+, which NSC Season 2 participants can choose to use if they are not using any of the three official trackers, including the Actxa Stride, that HPB issues. These additional models are available for trade-ups or direct purchase this year. Opt To Swap Into Swift+ From the Primary One student to the blue-collared worker to the 60-year-old silver-haired grandparent, Actxa’s company DNA has always been about incorporating smart technologies into innovative gadgets so consumers are empowered to live healthier, more active lifestyles. As such, Actxa has launched a Trade-In Program for NSC Season 2 – a fuss-free initiative that takes in all step trackers regardless of condition and brands, for an upgrade to either the Swift or Swift+. The Swift+ in particular packs in plenty of exciting new features to practically assist wearers in their daily dynamic lives. More than just monitoring your daily steps count, the Swift+ functions like a 24/7 fitness buddy thanks to the Activity Tracker which tabulates amount of calories burnt, active duration time and distance travelled on a daily basis. Another powerful addition is in utilising nano-coating technology to deliver Sweat/Rain/Splash/Swim Proof resistance, so users may indulge in water activities without worrying about losing their fitness data. Lifestyle helps aren’t forgotten, such as a Silent Alarm for jump-starting the day without waking others, as well as allowing the modern millennial the option of using the Swift+ for receiving call notifications (with Caller ID on screen), text message notifications as well as email notifications while on the go. “Actxa is very proud to be a Singaporean company supporting a nationwide initiative that encourages fellow Singaporeans to be active. In support of the National Steps Challenge, we are excited to launch a series of promotions that aim to put our fitness and activity trackers into the hands of everyone, inspiring them to lead active and healthier lives,” said Joel Chin, CEO of Actxa. All step trackers can be traded up from 1 Oct 2016 to 31 March 2017 at our list of recognised retail partners, located across 12 locations island wide. Each accepted tracker is entitled to a $15 discount off the Swift or Swift+ (U.P. $49.90 and $69.90). The discounted Swift and Swift+ will cost $34.90 and $54.90 respectively. About The National Steps Challenge The National Steps Challenge (NSC) is a physical activity initiative by the Health Promotion Board (HPB) to encourage Singapore residents to be more physically active every day, anytime and anywhere. After the rousing success of 2015’s inaugural launch, Season 2 kickstarted on 1 October 2016 and will end on 30 April 2017. The NSC is open to all Singaporeans, Permanent Residents and foreigners aged 18 and above at the point of registration with a valid NRIC or FIN. About Actxa The Actxa team was formed in 2015, steered by a team passionate to design, develop and deliver the latest technologies packed into fitness wearables that are not only affordable, but also fun to use and aesthetically right on point. That same year, Actxa became the appointed supplier of the steps tracker for the inaugural National Steps Challenge. Leading up to the anticipated launch of Season 2 on 1 October 2016, Actxa has again been chosen as the appointed supplier of steps tracker, in addition to being the official tech partner of the event. Truly, our company’s tagline to ‘Mind Your Fitness’ speaks of our single motivation to empower customers to embark on healthy lifestyles, through our range of innovative products such as activity trackers and a smart scale that are easily connected via a smart app – all platforms powered by our experience in technology and biomechanics. For further information, please contact: Marcus Soo Tel: +65 8765 0366 Email: marcus@actxa.com

  • Someone's Junklogue: Actxa Swift+

    I was killing time at Challenger the other day, when I saw a very cheap wearable – Actxa Swift / Swift+. They were going for $49.90 (Swift) / $69.90 (Swift+). If you’re not familiar with the name Actxa, National Steps Challenge first season used their tracker – the Actxa Stride, a simple but really nice tracker – to link up with the official app, Healthy 365. The Swift / Swift+ models got me excited – they seemed to be the upgraded version of the Stride model. Seeing how the National Steps Challenge season 2 has begun, I got that itch – when you don’t need something but you just want it. (On a side note, if you have not signed up for season 2, do sign up now! No loss and more to gain. More info here.) So I went to google for reviews. Sadly, the model is so local that I could find only one review, which wasn’t enough for the insatiable me. So I went out and bought it. This review is a compilation of what I found out and my thoughts post-purchase. The most important question Question – Can it be cheaper? Yes! I was checking out the prices, and there are two very good deals going on right now – while stocks last I guess. $10 off purchase on Hachi.tech From now until 31 Dec 2016, you can get $10 off if you use the code ACTXA10 when you purchase any Actxa product from Hachi.tech. $15 off if you trade your old Stride at Challenger retail stores. http://www.actxa.com/trade-in/This was the deal-maker for me. Because newer is better, right? It also got me running around to several Challenger stores and calling Challenger hotline. So here’s what I know for sure, that is not correctly updated on Challenger system, apparently. You can trade at any Challenger store it seems, despite what it said in the link or what the Challenger hotline guy said. Not all stores have Swift+ model – I saw some models at Plaza Singapura and Tiong Bahru Plaza. The aqua model looked nice and bright on screen but dull in real life. Disappointment to the max. It is also only available at the Tiong Bahru Plaza if you’re buying from retail store. Don’t be disappointed if you order it online and it doesn’t look like the colour you expected it to be. Why Swift+? I have one other wearable, Misfit Speedo. This very cool minimalist tracker makes it near impossible to replace its battery, which is not cool at all. In fact, I have diminished its aesthetic value in my attempts to pry off the back of the tracker to replace the battery (as instructed in the guide). I was already shopping around for an easier-to-maintain wearable since the beginning of the year, and had my eye on either Garmin Vivoactive or TomTom Spark Cardio. Both put me off with the general body bulk. I would have considered fitbit and jawbone but neither supported swimming. I was also considering Pebble 2, but since there were no reviews as of yet, so there’s that. Swift+ had me sold on these: waterproof (swim up to 1m depth. As of the time of this writing, I have not tried swimming with it. Shall update it soon enough, I suppose. Edit: It worked fine at at 1.2m pool and in hot shower.) lesser than $100 supports National Steps Challenge ($5 vouchers for the win!) Unpacking The tracker comes packed in a transparent box which I failed to take a photo of because I was so excited that I completely ravaged the packaging on public transport. Here’s a tip for buyers… open the packaging from the bottom. What’s in the box? Tracker Usb charging cable (you will have to plug it into a usb charger.) Booklet License (on the booklet. Do not lose it. You will need to retain your receipt for warranty as well.) Wearing Swift+ vs Stride With Stride, a twist of the wrist would activate the time on the wearable face. This is the one thing I miss most. The Swift / Swift+ requires the wearer to tap on the marked area on its surface to activate the surface. Tapping more toggles between the different data being collected by the tracker, such as number of steps, calories and distance walked. Swift+ wears awkward. I don’t know how to describe it any other way. So here’s a couple of photos to show you why. With Stride, the wearer inserts the band through the loop at the end of the band which is sort of the buckle of a standard watch, before pressing down the metal bit through the hole to secure the band. Swift+ has the user securing the band with the metal piece at the inner part first before putting the rest of the band through the free loop. This kind of cause the band to jump around. In the first season, one of the issues that was quite an irritant was the fact that the account was locked down to a single physical device. I had the misfortune of causing my Stride to go swimming and I had to go through the lengthy process of contacting the programme administrators to assist in the changing the device. With the season 2 roll out, or maybe slightly before, the user is able to use other devices and health apps to track the steps. Swift+ was not one of the HPB-issued devices. However, I should be able to sync the steps through the Actxa app option. The key word – should. It took a while before the steps were synced at all, and even so, it did not sync from the Actxa app, causing me to lose out on some 1500 steps. All in all, I would say that I have quite a bit of a gripe with the software and hardware, but I can live with those, so I won’t give up on the brand yet. Source: https://junklogue.wordpress.com/2016/11/15/actxa-swift/

  • Outsmart, Outweigh and Outwin with The Actxa Sense Smart Scale

    For Immediate Release Outsmart, Outweigh and Outwin with The Actxa Sense Smart Scale Actxa, Singapore’s smart wearables provider has launched the Sense Smart Scale, an intuitive digital body fat analyser designed to help the world register a fitter, healthier lifestyle. The Body Mass Index (BMI) is widely regarded as the quickest way to measure obesity – not just a weighty issue in other nations, but here in Singapore as well. BMI measures the relationship between a person’s weight and height, where the higher the reading, the higher the amount of fat in the body. The World Health Organization classifies a heathy reading between 18.5 and 24.99. However, according to a 2 April 2016 report by The Lancet journal¹, the number of people globally with a BMI over 30 stands at 641 million in 2014, a sharp rise from 105 million in 1975. In addition, because Asians, including Singaporeans, generally register higher percentages of body fat as opposed to Caucasians, local BMI benchmarks have been revised accordingly, where a reading of 27.5 kg/m² or more represents a high risk for cardiovascular diseases and diabetes. The latter in particular, has become one of the biggest drains on Singapore’s healthcare system – about 400,0002 have been diagnosed with the disease locally as of 2016. While studies show that Type 1 diabetes is strongly linked to genetics³ and incurable⁴, Type 2 diabetes can be managed through lifestyle changes⁵ such as diet, exercise and medication. In a Straits Times article dated 8 April 2016, Professor George Dailey⁶, who is based in the Diabetics & Endocrinology division at Scripps Clinic, California, shared that with proper weight management, pre-diabetics who lost five to seven percent of body weight and increased their exercise regime could halve the rate of progression from pre-diabetes to diabetes. With a possibility of one million Singaporean residents plagued by diabetes by 2050, the Ministry of Health declared the launch of War on Diabetes² in April last year. Speaking on his ministry’s budget in Parliament on 13 April, Minister for Health, Mr Gan Kim Yong outlined three key prongs in this fight against diabetes, one of which included promoting a healthier lifestyle and encouraging more to exercise. Still, BMI might not be the most accurate gauge of personal health, as challenged by two medical professors from the University of Pennsylvania⁷, who argued that “there is an urgent need for accurate, practical and affordable tools to measure fat and skeletal muscle, and biomarkers that can better predict the risks of diseases and mortality”. BMI in addition is not a recommended method for athletes, since individuals with muscular builds can lead to inaccurate readings. A typical scale also does not show other vital information, such as how much lean muscle you have – data that explains your body’s metabolism and calorie-burning ability. Track Your Health In Confidence Now you can take control of your journey to better health with the Actxa Sense Smart Scale, which on top of your BMI measurement, also helps to determine your lean muscle mass bone mass, and body fat percentage. More than just a telling sign of how well we fit into clothes, a body fat analyser could also point to possible future health problems. Based on these results, the smart machine then recommends the daily calorie intake required to maintain your current weight, thus helping users better understand what their body needs more or less of. In one step, the body fat analyser records data and syncs seamlessly through a smartphone with the Actxa App, where users can monitor body composition charts and progress over time. Accurate readings are obtained through bioelectrical impedance analysis, where a weak electrical current passes through your body. The technology is safe, toxic-free and non-invasive. Those who are serious about their health and fitness will additionally benefit from fitness trackers: Actxa Swift and Swift+. Working like a daily fitness buddy, the pedometers monitor your everyday health, fitness levels, and even sleep quality to help achieve a more balanced lifestyle. Upon reaching home – like a two-step approach – simply step onto the Sense Smart Scale and allow the body fat analyser to work, while simultaneously checking in on your smart fitness band. These two devices work in tandem to allow both individuals – and now families – to journey to better health together, as the Sense Smart Scale supports up to eight different profiles. An intuitive system automatically identifies its users, which makes it unnecessary to manually reset data or select profiles when taking measurements. Using the Actxa Sense Smart Scale is as easy as stepping on, and off. “Actxa is proud to have played a part in putting fitness and activity trackers into the hands of as many people as possible, in support of the National Steps Challenge. The launch of the Smart Sense completes the tools needed to track fitness goals, and so inspiring more Singaporeans to lead active and healthier lives,” said Joel Chin, CEO of Actxa. About Actxa The Actxa team was formed in 2015, steered by a team passionate to design, develop and deliver the latest technologies packed into fitness wearables that are not only affordable, but also fun to use and aesthetically right on point. That same year, Actxa became the appointed supplier of the steps tracker for the inaugural National Steps Challenge. Leading up to the anticipated launch of Season 2 on 1 October 2016, Actxa was again chosen as the appointed supplier of steps tracker, in addition to being the official tech partner of the event. Truly, our company’s tagline to ‘Mind Your Fitness’ speaks of our single motivation to empower customers to embark on healthy lifestyles, through our range of innovative products such as activity trackers and a smart scale that are easily connected via a smart app – all platforms powered by our experience in technology and biomechanics. For further information, please contact: Marcus Soo Tel: +65 8765 0366 Email: marcus@actxa.com Website: www.actxa.com REFERENCES 1. NCD Risk Factor Collaboration, “Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants,” The Lancet Volume 387, No. 10026, p1377–1396, 2 April 2016, http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(16)30054-X.pdf. 2. Mr Gan Kim Yong, “Speech by Mr Gan Kim Yong, Minister for Health, at the Opening Ceremony of World Diabetes Day Singapore 2016, 13 November 2016,” https://www.moh.gov.sg/content/moh_web/home/pressRoom/speeches_d/2016/speech-by-mr-gan-kim-yong–minister-for-health–at-the-opening-c0.html. 3. Joslin Diabetes Center, “Genetics & Diabetes: What’s Your Risk?” http://www.joslin.org/info/genetics_and_diabetes.html. 4. Mayo Clinic Staff, “Diseases and Conditions: Type 1 Diabetes,” Mayo Clinic, http://www.mayoclinic.org/diseases-conditions/type-1-diabetes/basics/definition/con-20019573. 5. The Diabetic Society of Singapore, “Resources: What Is Diabetes?” http://www.diabetes.org.sg/resources.html. 6. Jessie Lim, “The Straits Times: Singapore is No. 2 nation with most diabetics: 5 things about diabetes,” The Straits Times, http://www.straitstimes.com/singapore/singapore-is-no-2-nation-with-most-diabetics-5-things-about-diabetes. 7. Penn Medicine News, “Obesity/Mortality Paradox Demonstrates Urgent Need for More Refined Metabolic Measures,” Penn Medicine, https://www.pennmedicine.org/news/news-releases/2013/august/obesitymortality-paradox-demon.

bottom of page